Clinical Trials

NCT04929210 | ACTIVE_NOT_RECRUITING | PHASE4

411 participants

A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease

Study Type:: INTERVENTIONAL
Last Updated:: 2026-07-31
Start Date:: 2021-08-30
Completion:: 2026-08-04

Conditions

Arthritis, Psoriatic

Interventions

DRUG

No Results Yet

NCT04927494 | COMPLETED | NA

288 participants

Cervical Cancer Prevention for Black Adults

Study Type:: INTERVENTIONAL
Last Updated:: 2026-07-31
Start Date:: 2023-01-01
Completion:: 2025-05-10

Conditions

Cervical Cancer

Interventions

BEHAVIORAL

Results Available

NCT04912765 | RECRUITING | PHASE2

60 participants

Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC

Study Type:: INTERVENTIONAL
Last Updated:: 2026-07-31
Start Date:: 2021-04-15
Completion:: 2026-12-31

Conditions

Hepatocellular Carcinoma
Hepatocellular Cancer
Colorectal Cancer
Colorectal Carcinoma
Liver Metastases

Interventions

BIOLOGICAL
DRUG

No Results Yet

NCT04901195 | ACTIVE_NOT_RECRUITING | PHASE3

658 participants

A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa

Study Type:: INTERVENTIONAL
Last Updated:: 2026-07-31
Start Date:: 2021-05-27
Completion:: 2026-07-28

Conditions

Hidradenitis Suppurativa

Interventions

DRUG

No Results Yet

NCT04892173 | RECRUITING | PHASE3

500 participants

JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC

Study Type:: INTERVENTIONAL
Last Updated:: 2026-07-31
Start Date:: 2021-12-10
Completion:: 2028-06-30

Conditions

Carcinoma, Squamous Cell

Interventions

DRUG
RADIATION

No Results Yet

NCT04865172 | COMPLETED

44 participants

ECOCAPTURE for the Assessment of Apathy Under Real-life Conditions

Study Type:: OBSERVATIONAL
Last Updated:: 2026-07-31
Start Date:: 2022-05-20
Completion:: 2025-04-18

Conditions

Frontotemporal Dementia, Behavioral Variant
Alzheimer Disease

Interventions

OTHER

No Results Yet

NCT04847453 | ACTIVE_NOT_RECRUITING | PHASE1

24 participants

Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis

Study Type:: INTERVENTIONAL
Last Updated:: 2026-07-31
Start Date:: 2022-08-03
Completion:: 2028-06-30

Conditions

Recurrent AL Amyloidosis
Refractory AL Amyloidosis

Interventions

PROCEDURE
DRUG

No Results Yet

NCT04816006 | RECRUITING | NA

160 participants

Breast Cancer, Reasoning, and Activity Intervention

Study Type:: INTERVENTIONAL
Last Updated:: 2026-07-31
Start Date:: 2024-02-22
Completion:: 2028-07-31

Conditions

Breast Cancer
Breast Neoplasms
Anatomic Stage I Breast Cancer AJCC v8
Anatomic Stage II Breast Cancer AJCC v8
Anatomic Stage IIIA Breast Cancer AJCC v8
Cancer-related Cognitive Dysfunction

Interventions

BEHAVIORAL
OTHER

No Results Yet

NCT04811560 | RECRUITING | PHASE1/PHASE2

420 participants

A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)

Study Type:: INTERVENTIONAL
Last Updated:: 2026-07-31
Start Date:: 2021-05-19
Completion:: 2027-02-26

Conditions

Acute Leukemia

Interventions

DRUG

No Results Yet

NCT04770779 | ACTIVE_NOT_RECRUITING | PHASE3

258 participants

A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)

Study Type:: INTERVENTIONAL
Last Updated:: 2026-07-31
Start Date:: 2021-11-30
Completion:: 2024-04-11

Conditions

Transfusion-dependent Alpha-Thalassemia
Transfusion-dependent Beta-Thalassemia

Interventions

DRUG

Results Available

NCT04770753 | ACTIVE_NOT_RECRUITING | PHASE3

194 participants

A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Non-Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-NTDT)

Study Type:: INTERVENTIONAL
Last Updated:: 2026-07-31
Start Date:: 2021-12-20
Completion:: 2023-11-13

Conditions

Non-Transfusion-dependent Alpha-Thalassemia
Non-Transfusion-dependent Beta-Thalassemia

Interventions

DRUG

Results Available

NCT04763681 | COMPLETED | NA

54 participants

Couple HOPES and COVID-19

Study Type:: INTERVENTIONAL
Last Updated:: 2026-07-31
Start Date:: 2021-01-01
Completion:: 2024-01-31

Conditions

Posttraumatic Stress Disorder

Interventions

BEHAVIORAL

No Results Yet

NCT04747249 | COMPLETED | NA

29 participants

Psychological Care of Oncology Patients With Post-traumatic Stress in the Context of a COVID-19

Study Type:: INTERVENTIONAL
Last Updated:: 2026-07-31
Start Date:: 2021-06-18
Completion:: 2022-03-31

Conditions

Solid Carcinoma
Post Traumatic Stress Disorder
Covid19

Interventions

OTHER

Results Available

NCT04747054 | RECRUITING | PHASE3

102 participants

Study on the Efficacy of Treatment by Radiotherapy and Pembrolizumab in Newly Diagnosed Metastatic Head & Neck Cancers

Study Type:: INTERVENTIONAL
Last Updated:: 2026-07-31
Start Date:: 2021-12-01
Completion:: 2026-10-01

Conditions

Squamous Cell Carcinoma of Head and Neck

Interventions

DRUG
RADIATION

No Results Yet

NCT04737239 | COMPLETED

61 participants

Corticosteroid Injection Effectiveness in Carpel Tunnel Patients With Negative or Mild EMG Studies

Study Type:: OBSERVATIONAL
Last Updated:: 2026-07-31
Start Date:: 2020-12-23
Completion:: 2026-03-22

Conditions

Carpal Tunnel Syndrome

Interventions

OTHER

No Results Yet

NCT04728165 | COMPLETED

27 participants

Anti-Inflammatory Effects of Time-Restricted Feeding

Study Type:: OBSERVATIONAL
Last Updated:: 2026-07-31
Start Date:: 2021-06-09
Completion:: 2023-07-28

Conditions

Psoriasis
Systemic Inflammation

No Results Yet

NCT04722146 | ACTIVE_NOT_RECRUITING | PHASE1

140 participants

A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma

Study Type:: INTERVENTIONAL
Last Updated:: 2026-07-31
Start Date:: 2021-03-12
Completion:: 2025-10-03

Conditions

Multiple Myeloma

Interventions

DRUG

No Results Yet

NCT04720625 | COMPLETED | NA

757 participants

Adapt2Quit - An Adaptive Motivational System for Socio-Economically Disadvantaged Smokers

Study Type:: INTERVENTIONAL
Last Updated:: 2026-07-31
Start Date:: 2021-06-28
Completion:: 2024-10-10

Conditions

Tobacco Smoking

Interventions

BEHAVIORAL

Results Available

NCT04691323 | COMPLETED | NA

68 participants

The Longitudinal Relationship of HU Adherence to HRQOL, Barriers to Adherence and Habit in SCD.

Study Type:: INTERVENTIONAL
Last Updated:: 2026-07-31
Start Date:: 2021-03-02
Completion:: 2024-06-18

Conditions

Sickle Cell Disease
Sickle B+ Thalassemia
Sickle Beta Zero Thalassemia
Sickle Cell Hemoglobin C

Interventions

OTHER

No Results Yet

NCT04688411 | COMPLETED | NA

36 participants

An mHealth Strategy to Improve Medication Adherence in Adolescents With Sickle Cell Disease

Study Type:: INTERVENTIONAL
Last Updated:: 2026-07-31
Start Date:: 2020-09-28
Completion:: 2025-09-16

Conditions

Sickle Cell Disease
Sickle Beta Zero Thalassemia
Sickle B+ Thalassemia
Sickle Cell Hemoglobin C

Interventions

BEHAVIORAL

No Results Yet

NCT04671667 | RECRUITING | PHASE2

188 participants

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

Study Type:: INTERVENTIONAL
Last Updated:: 2026-07-31
Start Date:: 2021-04-27
Completion:: 2029-06-30

Conditions

Recurrent Head and Neck Squamous Cell Carcinoma
Recurrent Hypopharyngeal Squamous Cell Carcinoma
Recurrent Laryngeal Squamous Cell Carcinoma
Recurrent Oral Cavity Squamous Cell Carcinoma
Recurrent Oropharyngeal Squamous Cell Carcinoma

Interventions

DRUG
PROCEDURE
RADIATION
BIOLOGICAL

No Results Yet

NCT04658862 | ACTIVE_NOT_RECRUITING | PHASE3

518 participants

A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder

Study Type:: INTERVENTIONAL
Last Updated:: 2026-07-31
Start Date:: 2020-12-07
Completion:: 2026-12-30

Conditions

Urinary Bladder Neoplasms

Interventions

BIOLOGICAL
DRUG
RADIATION

No Results Yet

NCT04657289 | ACTIVE_NOT_RECRUITING | PHASE3

451 participants

A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)

Study Type:: INTERVENTIONAL
Last Updated:: 2026-07-31
Start Date:: 2021-07-14
Completion:: 2027-02-04

Conditions

Neovascular Age-related Macular Degeneration (nAMD)

Interventions

DRUG
DEVICE

No Results Yet

NCT04656652 | ACTIVE_NOT_RECRUITING | PHASE3

605 participants

Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)

Study Type:: INTERVENTIONAL
Last Updated:: 2026-07-31
Start Date:: 2020-12-21
Completion:: 2024-05-10

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG

Results Available

NCT04652960 | ACTIVE_NOT_RECRUITING | PHASE1

38 participants

Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome

Study Type:: INTERVENTIONAL
Last Updated:: 2026-07-31
Start Date:: 2021-10-21
Completion:: 2026-12-03

Conditions

Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8
Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8
Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v8

Interventions

PROCEDURE
DRUG
BIOLOGICAL

No Results Yet

NCT04641442 | ACTIVE_NOT_RECRUITING | PHASE2

17 participants

Study to Evaluate the Efficacy, Safety and Tolerability of MAS825 in Patients With Monogenic IL-18 Driven Autoinflammatory Diseases, Including NLRC4-GOF, XIAP Deficiency, or CDC42 Mutations

Study Type:: INTERVENTIONAL
Last Updated:: 2026-07-31
Start Date:: 2020-12-18
Completion:: 2025-10-14

Conditions

NLRC4-GOF, AIFEC (Autoinflammation With Infantile Enterocolitis), XIAP Deficiency, CDC42 Mutations

Interventions

BIOLOGICAL

No Results Yet

NCT04640623 | ACTIVE_NOT_RECRUITING | PHASE2

220 participants

A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy

Study Type:: INTERVENTIONAL
Last Updated:: 2026-07-31
Start Date:: 2020-12-18
Completion:: 2025-07-03

Conditions

Urinary Bladder Neoplasms

Interventions

DRUG
BIOLOGICAL

Results Available

NCT04631224 | COMPLETED

40 participants

Longitudinal Analysis of Oral Communication in Friedreich's Ataxia

Study Type:: OBSERVATIONAL
Last Updated:: 2026-07-31
Start Date:: 2015-02-28
Completion:: 2016-12-31

Conditions

Friedreich Ataxia

No Results Yet

NCT04621760 | COMPLETED | NA

189 participants

The OPENS Trial: Offering Women PrEP (Aim 1)

Study Type:: INTERVENTIONAL
Last Updated:: 2026-07-31
Start Date:: 2021-05-03
Completion:: 2022-10-24

Conditions

Human Immunodeficiency Virus Transmission
Sexually Transmitted Diseases

Interventions

BEHAVIORAL

Results Available

NCT04617925 | COMPLETED | PHASE2

35 participants

A Study of Belantamab Mafodotin in Patients With Relapsed or Refractory AL Amyloidosis

Study Type:: INTERVENTIONAL
Last Updated:: 2026-07-31
Start Date:: 2021-02-26
Completion:: 2025-07-17

Conditions

AL Amyloidosis

Interventions

DRUG

No Results Yet

NCT04616534 | ACTIVE_NOT_RECRUITING | PHASE1

14 participants

Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors

Study Type:: INTERVENTIONAL
Last Updated:: 2026-07-31
Start Date:: 2021-06-01
Completion:: 2025-04-01

Conditions

Advanced Fallopian Tube Carcinoma
Advanced Malignant Solid Neoplasm
Advanced Ovarian Carcinoma
Advanced Pancreatic Adenocarcinoma
Advanced Primary Peritoneal Carcinoma
Fallopian Tube High Grade Serous Adenocarcinoma
Metastatic Pancreatic Adenocarcinoma
Ovarian High Grade Serous Adenocarcinoma
Platinum-Resistant Fallopian Tube Carcinoma
Platinum-Resistant Ovarian Carcinoma
Platinum-Resistant Primary Peritoneal Carcinoma
Primary Peritoneal High Grade Serous Adenocarcinoma
Stage II Pancreatic Cancer AJCC v8
Stage III Fallopian Tube Cancer AJCC v8
Stage III Ovarian Cancer AJCC v8
Stage III Pancreatic Cancer AJCC v8
Stage III Primary Peritoneal Cancer AJCC v8
Stage IV Fallopian Tube Cancer AJCC v8
Stage IV Ovarian Cancer AJCC v8
Stage IV Pancreatic Cancer AJCC v8
Stage IV Primary Peritoneal Cancer AJCC v8
Unresectable Pancreatic Adenocarcinoma

Interventions

PROCEDURE
DRUG

Results Available

NCT04595747 | ACTIVE_NOT_RECRUITING | PHASE2

48 participants

Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST)

Study Type:: INTERVENTIONAL
Last Updated:: 2026-07-31
Start Date:: 2021-05-03
Completion:: 2027-07-31

Conditions

Locally Advanced Gastrointestinal Stromal Tumor
Locally Advanced Sarcoma
Metastatic Gastrointestinal Stromal Tumor
Metastatic Sarcoma
Stage III Gastric and Omental Gastrointestinal Stromal Tumor AJCC v8
Stage III Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor AJCC v8
Stage IV Gastric and Omental Gastrointestinal Stromal Tumor AJCC v8
Stage IV Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor AJCC v8

Interventions

PROCEDURE
DRUG

No Results Yet

NCT04557098 | ACTIVE_NOT_RECRUITING | PHASE2

194 participants

A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

Study Type:: INTERVENTIONAL
Last Updated:: 2026-07-31
Start Date:: 2020-09-17
Completion:: 2021-11-09

Conditions

Hematological Malignancies

Interventions

DRUG

No Results Yet

NCT04554914 | ACTIVE_NOT_RECRUITING | PHASE2

190 participants

A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases

Study Type:: INTERVENTIONAL
Last Updated:: 2026-07-31
Start Date:: 2021-07-14
Completion:: 2027-06-30

Conditions

Epstein-Barr Virus (EBV)-Associated Diseases
EBV+ Lymphoproliferative Disease With Primary Immunodeficiency (EBV+ PID LPD)
EBV+ Lymphoproliferative Disease With Acquired (Non-congenital) Immunodeficiency (EBV+ AID LPD)
EBV+ Posttransplant Lymphoproliferative Disease in Central Nervous System (EBV+ CNS PTLD)
EBV+ Post-transplant Lymphoproliferative Disease (EBV+ PTLD)
Solid Organ Transplant Complications
Lymphoproliferative Disorders
Allogeneic Hematopoietic Cell Transplant
Stem Cell Transplant Complications
EBV+ Sarcomas
Leiomyosarcoma

Interventions

BIOLOGICAL

No Results Yet

NCT04521764 | RECRUITING | PHASE1

54 participants

A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer

Study Type:: INTERVENTIONAL
Last Updated:: 2026-07-31
Start Date:: 2020-09-23
Completion:: 2027-08-15

Conditions

Anatomic Stage IV Breast Cancer AJCC v8
Invasive Breast Carcinoma
Metastatic Breast Adenocarcinoma
Recurrent Breast Carcinoma
Stage IV Breast Cancer AJCC v6 and v7

Interventions

BIOLOGICAL
PROCEDURE

No Results Yet

NCT04518748 | ACTIVE_NOT_RECRUITING | PHASE1

70 participants

Combined Y-90 Selective Internal Radiation Therapy (Y-90 SIRT) and Stereotactic Body Radiation Therapy (SBRT) in Hepatic Malignancy.

Study Type:: INTERVENTIONAL
Last Updated:: 2026-07-31
Start Date:: 2020-09-16
Completion:: 2028-05-31

Conditions

Liver Malignancy

Interventions

DRUG
DEVICE
RADIATION
DIAGNOSTIC_TEST

No Results Yet

NCT04514497 | ACTIVE_NOT_RECRUITING | PHASE1

29 participants

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer

Study Type:: INTERVENTIONAL
Last Updated:: 2026-07-31
Start Date:: 2021-10-20
Completion:: 2025-02-15

Conditions

Metastatic Lung Small Cell Carcinoma
Metastatic Malignant Solid Neoplasm
Metastatic Neuroendocrine Carcinoma
Metastatic Pancreatic Adenocarcinoma
Stage III Lung Cancer AJCC v8
Stage III Pancreatic Cancer AJCC v8
Stage IV Lung Cancer AJCC v8
Stage IV Pancreatic Cancer AJCC v8
Unresectable Lung Small Cell Carcinoma
Unresectable Malignant Solid Neoplasm
Unresectable Neuroendocrine Carcinoma
Unresectable Pancreatic Adenocarcinoma

Interventions

PROCEDURE
DRUG

Results Available

NCT04491942 | ACTIVE_NOT_RECRUITING | PHASE1

74 participants

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer

Study Type:: INTERVENTIONAL
Last Updated:: 2026-07-31
Start Date:: 2021-08-25
Completion:: 2027-06-30

Conditions

Advanced Bile Duct Carcinoma
Advanced Breast Carcinoma
Advanced Cervical Carcinoma
Advanced Endometrial Carcinoma
Advanced Esophageal Carcinoma
Advanced Gastric Carcinoma
Advanced Head and Neck Carcinoma
Advanced Lung Non-Small Cell Carcinoma
Advanced Lung Small Cell Carcinoma
Advanced Malignant Solid Neoplasm
Advanced Ovarian Carcinoma
Advanced Penile Carcinoma
Advanced Pleural Malignant Mesothelioma
Advanced Urothelial Carcinoma
Anatomic Stage III Breast Cancer AJCC v8
Anatomic Stage IV Breast Cancer AJCC v8
Clinical Stage III Gastric Cancer AJCC v8
Clinical Stage IV Gastric Cancer AJCC v8
Stage III Cervical Cancer AJCC v8
Stage III Distal Bile Duct Cancer AJCC v8
Stage III Intrahepatic Bile Duct Cancer AJCC v8
Stage III Lung Cancer AJCC v8
Stage III Ovarian Cancer AJCC v8
Stage III Penile Cancer AJCC v8
Stage III Pleural Diffuse Malignant Mesothelioma AJCC v8
Stage IV Cervical Cancer AJCC v8
Stage IV Distal Bile Duct Cancer AJCC v8
Stage IV Intrahepatic Bile Duct Cancer AJCC v8
Stage IV Lung Cancer AJCC v8
Stage IV Ovarian Cancer AJCC v8
Stage IV Penile Cancer AJCC v8
Stage IV Pleural Diffuse Malignant Mesothelioma AJCC v8
Triple-Negative Breast Carcinoma
Unresectable Urothelial Carcinoma

Interventions

DRUG

No Results Yet

NCT04460937 | ACTIVE_NOT_RECRUITING | PHASE1

4 participants

Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction Cancers

Study Type:: INTERVENTIONAL
Last Updated:: 2026-07-31
Start Date:: 2021-04-09
Completion:: 2024-03-29

Conditions

Clinical Stage III Esophageal Adenocarcinoma AJCC v8
Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8
Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
Clinical Stage IV Esophageal Adenocarcinoma AJCC v8
Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8
Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8
Clinical Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8
Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8
Clinical Stage IVB Esophageal Adenocarcinoma AJCC v8
Clinical Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8
Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8
Distal Esophagus Adenocarcinoma
Gastric Cardia Adenocarcinoma
Metastatic Esophageal Adenocarcinoma
Metastatic Esophageal Squamous Cell Carcinoma
Metastatic Gastroesophageal Junction Adenocarcinoma
Metastatic Malignant Neoplasm in the Brain
Metastatic Malignant Neoplasm in the Leptomeninges
Pathologic Stage III Esophageal Adenocarcinoma AJCC v8
Pathologic Stage III Esophageal Squamous Cell Carcinoma AJCC v8
Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8
Pathologic Stage IIIA Esophageal Squamous Cell Carcinoma AJCC v8
Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8
Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8
Pathologic Stage IIIB Esophageal Squamous Cell Carcinoma AJCC v8
Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8
Pathologic Stage IV Esophageal Adenocarcinoma AJCC v8
Pathologic Stage IV Esophageal Squamous Cell Carcinoma AJCC v8
Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8
Pathologic Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8
Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8
Pathologic Stage IVB Esophageal Adenocarcinoma AJCC v8
Pathologic Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8
Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8
Postneoadjuvant Therapy Stage III Esophageal Adenocarcinoma AJCC v8
Postneoadjuvant Therapy Stage III Esophageal Squamous Cell Carcinoma AJCC v8
Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
Postneoadjuvant Therapy Stage IIIA Esophageal Adenocarcinoma AJCC v8
Postneoadjuvant Therapy Stage IIIA Esophageal Squamous Cell Carcinoma AJCC v8
Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8
Postneoadjuvant Therapy Stage IIIB Esophageal Adenocarcinoma AJCC v8
Postneoadjuvant Therapy Stage IIIB Esophageal Squamous Cell Carcinoma AJCC v8
Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8
Postneoadjuvant Therapy Stage IV Esophageal Adenocarcinoma AJCC v8
Postneoadjuvant Therapy Stage IV Esophageal Squamous Cell Carcinoma AJCC v8
Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
Postneoadjuvant Therapy Stage IVA Esophageal Adenocarcinoma AJCC v8
Postneoadjuvant Therapy Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8
Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8
Postneoadjuvant Therapy Stage IVB Esophageal Adenocarcinoma AJCC v8
Postneoadjuvant Therapy Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8
Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8
Unresectable Esophageal Adenocarcinoma
Unresectable Esophageal Carcinoma
Unresectable Esophageal Squamous Cell Carcinoma
Unresectable Gastroesophageal Junction Adenocarcinoma

Interventions

DRUG
RADIATION

Results Available

NCT04458922 | ACTIVE_NOT_RECRUITING | PHASE2

27 participants

Testing Atezolizumab in People 2-17 Years Old With Clear Cell Sarcoma or Advanced Chondrosarcoma

Study Type:: INTERVENTIONAL
Last Updated:: 2026-07-31
Start Date:: 2020-10-05
Completion:: 2022-11-28

Conditions

Central Chondrosarcoma, Grade 2
Central Chondrosarcoma, Grade 3
Dedifferentiated Chondrosarcoma
Metastatic Clear Cell Sarcoma of Soft Tissue
Metastatic Primary Central Chondrosarcoma
Unresectable Primary Central Chondrosarcoma

Interventions

DRUG
PROCEDURE

Results Available